$10m Exclusive Dist Agreement with EZZ Life Sciences
Filed with ASX · · 4 pages · English
Earlier from Xenitra
- Quarterly Activities/Appendix 4C Cash Flow Report
- Aumake Enters High-Growth China OTC Medicine Market
- $1.5m Raised to Support Business Growth
- Trading Halt
- Quarterly Activities/Appendix 5B Cash Flow Report
Later from Xenitra
- EZZ: EZZ Appoints Aumake in $10m Exclusive Dist Agreement
- Half Yearly Report and Accounts
- $30m Danone - Rockcheck Strategic Partnership
- OPAL Token & Xen Shop Launch - Next-Gen Digital Commerce
- Acquisition of Fukang OTC Pharmacy
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra